Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00292344
Other study ID # TRA-04-01
Secondary ID
Status Completed
Phase Phase 4
First received February 13, 2006
Last updated April 17, 2009
Start date June 2004
Est. completion date August 2005

Study information

Verified date February 2006
Source The University of Texas Health Science Center, Houston
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment.


Description:

During short-term study, adult U.S. students in Mexico (n = 310) with acute diarrhea (≥ 3 unformed stools with enteric symptoms) were enrolled in a double-blind, randomized trial wherein they were given rifaximin 200 mg three times a day for 3 days (R) (n = 102), loperamide 4 mg initially followed by 2 mg after each unformed stool not to exceed 8 mg/day for 2 days (L) (n = 104) or both drugs in the same dosage schedule (L/R) (n = 104). The major outcome parameter was time from initiation of therapy until passage of the last unformed stool before becoming well (TLUS).


Recruitment information / eligibility

Status Completed
Enrollment 316
Est. completion date August 2005
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Inclusion criteria include: IRB approval; signing of a consent form;18 years of age or older, providing of an unformed pre-treatment stool; females must be non-pregnant and not nursing.

Exclusion Criteria:

- Exclusion criteria include: diarrhea longer than 72 hours; moderate or severe dehydration, pregnancy or breast feeding, receipt of trimethoprim-sulfamethoxazole, azalide, doxycycline, or a fluoroquinolone in the past week; unstable medical condition; hypersensitivity to rifaximin or rifampin; fever (>100.6o F) or bloody diarrhea.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Rifaximin and loperamide


Locations

Country Name City State
Mexico Clinica Londres Morelos Cuernavaca Morelos
Mexico Universidad Autonoma de Guadalajara Guadalajara Jalisco
Mexico University of Arizona, Colegio Guadalajara Guadalajara Jalisco
Mexico University of San Diego at Iteso Guadalajara Jalisco

Sponsors (2)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston Valeant Pharmaceuticals International, Inc.

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary The major outcome parameter was time from initiation of therapy until passage of the last unformed stool before becoming well (TLUS).
Secondary Secondary Outcome Variables:
Secondary 1. Time to passage of last unformed stool - standard definition of TLUS for antibiotics (18, 20) where wellness is declared at any time during 5 days regardless of later recurrence of continuing illness during the observation period;
Secondary 2. Number of unformed stools passed during two days of therapy;
Secondary 3. Number of unformed stools passed during the five days of study;
Secondary 4. Improvement in diarrhea (<half the number of daily entry unformed stools in 24 hours) by 24 hours and 48 hours;
Secondary 5. Treatment failure defined as: a. failure to achieve wellness during five days of study (achieve a TLUS-5 d); b. Deterioration during treatment and removed from further clinical evaluation, or, c. Occurrence of a relapse after achieving wellness during
Secondary 6. Occurrence of relapse during five day surveillance (occurrence of diarrhea after having a TLUS);
Secondary 7. TLUS in 48 hours - last unformed stool passed during the 48 hours that loperamide is being given (rapid symptomatic improvement);
Secondary 8. Number of days of moderate or severe enteric symptoms;
Secondary 9. Number of days passing any number of unformed stools plus any degree (mild, moderate or severe) of daily enteric symptoms (must have both present each day);
Secondary 10. Subjects global assessment of efficacy by day of study;
Secondary 11. Number of hours where schedule of activities were altered because of illness;
Secondary 12. Number of hours confined to bed because of diarrhea;
Secondary 13. Dropped from study due to adverse reaction;
Secondary 14. Number of doses of loperamide (or loperamide placebos) taken;
Secondary 15. Microbiologic eradication/failure.
See also
  Status Clinical Trial Phase
Completed NCT00564863 - Dose-Finding Study of CS19 Expressing ETEC Challenge Strains Phase 1
Completed NCT00564577 - Dose-Finding Study of WS6788A and LSN03-016011/A Enterotoxigenic E. Coli ETEC Challenge Strains That Express CS17 Phase 1
Completed NCT00993681 - Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study Phase 3
Terminated NCT01005849 - Probiotics and the Prevention of Traveler's Diarrhea Phase 4
Completed NCT02498301 - Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD N/A
Withdrawn NCT00875875 - Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea Phase 4
Completed NCT00524004 - Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbD Phase 2
Terminated NCT02920242 - A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea. Phase 3